AVOVA-1

Aivita Biomedical, Inc. · Phase 2 active Biologic

AVOVA-1 is an allogeneic cell therapy derived from umbilical cord tissue that aims to promote tissue regeneration and reduce inflammation.

AVOVA-1 is an allogeneic cell therapy derived from umbilical cord tissue that aims to promote tissue regeneration and reduce inflammation. Used for Osteoarthritis or joint degenerative disease (investigational).

At a glance

Generic name	AVOVA-1
Sponsor	Aivita Biomedical, Inc.
Drug class	Allogeneic cell therapy
Modality	Biologic
Therapeutic area	Regenerative Medicine / Immunology
Phase	Phase 2

Mechanism of action

AVOVA-1 consists of mesenchymal stem cells or similar regenerative cells sourced from umbilical cord tissue. These cells are believed to work through immunomodulatory and paracrine mechanisms, secreting anti-inflammatory factors and promoting endogenous repair processes. The therapy is designed to address degenerative or inflammatory conditions by enhancing tissue healing and reducing pathological inflammation.

Approved indications

Osteoarthritis or joint degenerative disease (investigational)

Common side effects

No common side effects on file.

Key clinical trials

Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AVOVA-1 CI brief — competitive landscape report
AVOVA-1 updates RSS · CI watch RSS
Aivita Biomedical, Inc. portfolio CI